{
    "organizations": [],
    "uuid": "042bc6a050cfcc6cbf17e354e656dbaadbe34273",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biohaven-announces-robust-clinical/brief-biohaven-announces-robust-clinical-data-with-single-dose-rimegepant-that-defines-acute-and-durable-benefits-to-patients-idUSFWN1RX12L",
    "ord_in_thread": 0,
    "title": "BRIEF-Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 22 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:\n* BIOHAVEN ANNOUNCES ROBUST CLINICAL DATA WITH SINGLE DOSE RIMEGEPANT THAT DEFINES ACUTE AND DURABLE BENEFITS TO PATIENTS\n* BIOHAVEN PHARMACEUTICAL HOLDING SAYS BROAD AND CLINICALLY IMPORTANT BENEFITS BEYOND INITIAL REGISTRATIONAL ENDPOINTS ARE NOW REPORTED.\n* BIOHAVEN- RIMEGEPANT FIRST ORAL CGRP RECEPTOR ANTAGONIST TO DELIVER POSITIVE DATA ON PAIN FREEDOM IN TWO PIVOTAL PHASE 3 TRIALS IN ACUTE TREATMENT OF MIGRAINE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-23T05:08:00.000+03:00",
    "crawled": "2018-04-23T05:26:09.043+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "biohaven",
        "pharmaceutical",
        "holding",
        "company",
        "ltd",
        "biohaven",
        "announces",
        "robust",
        "clinical",
        "data",
        "single",
        "dose",
        "rimegepant",
        "defines",
        "acute",
        "durable",
        "benefit",
        "patient",
        "biohaven",
        "pharmaceutical",
        "holding",
        "say",
        "broad",
        "clinically",
        "important",
        "benefit",
        "beyond",
        "initial",
        "registrational",
        "endpoint",
        "reported",
        "rimegepant",
        "first",
        "oral",
        "cgrp",
        "receptor",
        "antagonist",
        "deliver",
        "positive",
        "data",
        "pain",
        "freedom",
        "two",
        "pivotal",
        "phase",
        "trial",
        "acute",
        "treatment",
        "migraine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}